Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFUGEM: Abraxane Combinations in Metastatic Pancreatic Cancer
NCT01964534Phase 2Unknown
- Sponsor
- GERCOR
- Start
- Dec 2013
- Primary completion
- Feb 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel (2 arms), sponsored by GERCOR. Primary endpoint: Progression-Free Survival at 4 months. Status: unknown.
02
Drugs
nab-paclitaxel
Beyond the preview
Go deeper on NCT01964534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964534.